Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-08-15
2006-08-15
Kaushal, Sumesh (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S069100, C435S320100, C435S325000, C435S455000, C424S093100
Reexamination Certificate
active
07090837
ABSTRACT:
This disclosure provides lentiviral vectors containing an attachment incompetent fusogenic polypeptide and a heterologous targeting polypeptide. Also provided are lentiviral packaging constructs, lentiviral packaging systems, and lentiviral gene delivery systems. Finally, methods of transducing a cell and methods of targeting a gene to a cell or tissue using the disclosed lentiviral vectors and systems are also provided.
REFERENCES:
Sandrin et al Blood 100(3):823-832, 2002.
Bosch et al J. Gen. Virol. 82:2485-2494, 2001.
Spiegel et al J. Virol. 72(6):5296-5302, 1998.
Juengst BMJ, 326:1410-11, 2003.
Check NATURE 422:7, 2003.
Couzin et al, SCIENCE 307:1028, 2005.
Rosenberg et al, SCIENCE 287:1751, 2000.
Anderson, NATURE 392:25-30, 1998.
Aldovini and Young, “Mutations of RNA and Protein Sequences Involved in Human Immunodeficiency Virus Type 1 Packaging Result in Production of Noninfectious Virus.”J. Virol., 64:1920-1926, 1990.
Chan and Kim, “HIV Entry and Its Inhibition.”Cell, 93:681-684, 1998.
Dull et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System.”J. Virol., 72:8463-8471, 1998.
Feinberg et al., “The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.”Proc. Natl. Acad. Sci. USA, 88:4045-4049, 1991.
Finer et al., “kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes.”Blood, 83:43-50, 1994.
Geigenmuller and Linial, “Specific Binding of Human Immunodeficiency virus Type 1 (HIV-1) Gag-Derived Proteins to a 5′ HIV-1 Genomic RNA Sequence.”J. Virol., 70:667-671, 1996.
Kim et al., “A Short Sequence Upstream of the 5′ Major Splice Site is Important for Encapsidation of HIV-1 Genomic RNA.”Virology, 198:336-340, 1994.
Lamb, “Paramyxovirus Fusion: A Hypothesis for Changes.”Virology, 197:1-11, 1993.
Leavitt et al., “Human Immunodeficiency Virus Type 1 Integrase Mutants Retain In Vitro Integrase Activity yet Fail To Integrate Viral DNA Efficiently during Infection.”J. Virol., 70:721-728, 1996.
Lin et al., “Receptor-Specific Targeting Mediated by the Coexpression of a Targeted Murine Leukemia Virus Envelope Protein and a Binding-Defective Influenza Hemagglutinin Protein.”Hum. Gene Ther., 12:323-332, 2001.
Lin and Cannon, “Use of pseudotype retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype).”Virus Res., 83:43-56, 2002.
Luban and Goff, “Mutational Analysis ofcis-Acting Packaging Signals in Human Immunodeficiency Virus Type 1 RNA.”J. Virol., 68:3784-3793, 1994.
McBride and Panganiban, “The Human Immunodeficiency Virus Type 1 Encapsidation Site Is a Multipartite RNA Element Composed of Functional Hairpin Structures.”J. Virol., 70:2963-2973, 1996.
Miyoshi et al., “Development of a Self-Inactivating Lentivirus Vector.”J. Virol., 72:8150-8157, 1998.
Naldini et al., “Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.”Proc. Natl. Acad. Sci. USA, 93:11382-11388, 1996.
Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector.”Science, 272:263-267, 1996.
Ory et al., “A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.”Proc. Natl. Acad. Sci. USA, 93:11400-11406, 1996.
Paillart et al., “A loop-loop “kissing” complex is the essential part of the dimer linkage of genomic HIV-1 RNA.”Proc. Natl. Acad. Sci. USA, 93:5572-5577, 1996.
Vicenzi et al., “An Integration-Defective U5 Deletion Mutant of Human Immunodeficiency Virus Type 1 Reverts by Eliminating Additional Long Terminal Repeat Sequences.”J. Virol., 68:7879-7890, 1994.
Wyatt and Sodroski, “The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens.”Science, 280:1884-1888, 1998.
Zhang et al., “Nascent Human Immunodeficiency Virus Type 1 Reverse Transcription Occurs within an Enveloped Particle.”J. Virol., 69:3675-3682, 1995.
Zhang et al., “Endogenous Reverse Transcription of Human Immunodeficiency Virus Type 1 in Physiological Microenvironments: an Important Stage for Viral Infection of Nondividing Cells.”J. Virol., 70:2809-2824, 1996.
Zufferey et al., “Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery.”J. Virol., 72:9873-9880, 1998.
Zufferey et al., “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.”Nature Biotechnol., 15:871-875, 1997.
Marr Robert
Spencer Brian
Verma Inder M.
Kaushal Sumesh
Klarquist & Sparkman, LLP
The Salk Institute for Biological Studies
LandOfFree
Compositions and methods for tissue specific targeting of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for tissue specific targeting of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for tissue specific targeting of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3637869